cancers

an Open Access Journal by MDPI

IMPACT FACTOR 4.5

Indexed in: PubMed

CITESCORE 8.0

Neurofibromatosis: Clinical and Genetic Findings

Guest Editors:

Dr. Rianne Oostenbrink
ENCORE-NF1 Center, Department of General Pediatrics, Erasmus MC, 3015 GD Rotterdam, The Netherlands

Dr. Ignaci Blanco
Metropolitana Nord Laboratory, Germans Trias i Pujol University Hospital, 08916 Badalona, Spain

Dr. Enrico Opocher
Pediatric Hematology, Oncology and Stem Cell Transplant Division, Padua University Hospital, Via Giustiniani 3, 35128 Padua, Italy

Deadline for manuscript submissions:
15 December 2024

Message from the Guest Editors

Neurofibromatosis type 1 (NF1), NF2-related schwannomatosis (NF2), and non-NF2-related schwannomatosis (SWN) are rare genetic disorders predisposing to the development of various tumors of the central and peripheral nervous systems. Although often benign, these neoplasms can still cause significant morbidity due to their size and/or location and are rarely amenable to surgical resection. It is therefore essential to translate pre-clinical advances into more effective treatment options for many of these tumors. To position these treatments, it is essential to understand the natural course, disease modifiers, and biomarkers. Finally, we are in need of a wider consensus on the preferred main outcomes of these potential treatments, including neurologic morbidity, vision, and ultimately, daily functioning and quality of life.

In this Special Issue, we welcome original research articles and comprehensive review articles focusing on the disease course, disease modifiers, and treatments of tumors in patients with neurofibromatosis type 1, NF2-related schwannomatosis, and non-NF2-related schwannomatosis, aiming for significant advancements in this challenging yet fascinating field.

cancers

IMPACT FACTOR 4.5 | Indexed in: PubMed | CITESCORE 8.0

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
𝕏@Cancers_MDPI